Parkinson's Disease Clinical Trial
Official title:
Systematic Characterization of the Cellular Proteome From Human Leukocytes of Glaucoma Patients in Comparison With Patients With Parkinson's Disease
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular
neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion
cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is
known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier
studies the investigators could demonstrate that the process of apoptosis is reflected in
circulating leukocytes by different parameters, like differential mRNA expression and an
increased fragmentation of the DNA. Such alterations point out a relationship between
cellular stress and apoptotic events.
Based on the results of mRNA-expression the investigators also expect alterations on the
protein level.
This study is, therefore, designed to characterize the proteome related to the proteins
involved in cell death related pathways.
Thus, the expression pattern of several proteins in leukocytes from patients with primary
open angle glaucoma will be analyzed by techniques like Western-blot and tandem mass
spectrometry. These samples will be compared with samples from healthy controls. In
addition, they will also be compared with samples from patients with Parkinson's disease.
Since glaucoma is a neurodegenerative disease, these patients will be included as positive
controls in this study.
Hypothesis:
Differences in the proteome concerning cell death pathways of glaucoma patients correspond
to the differences in the mRNA expression of these patients.
Specific aims:
Characterization of the cellular proteome from human leukocytes of glaucoma patients
compared to healthy controls and patients with Parkinson's disease.
Background:
Glaucoma is a worldwide leading cause of blindness. The key feature of this ocular
neuropathy is characterized by an excavating optic nerve head. Loss of retinal ganglion
cells is the final end point in blinding diseases of the optic nerve such as glaucoma. It is
known that neuronal cell death in glaucoma occurs by an apoptotic mechanism. In earlier
studies we could demonstrate that this cell death is reflected in circulating leukocytes by
different parameters, like differential mRNA expression, and an increased fragmentation of
the DNA. The differences in mRNA expression indicate a close relationship to cellular stress
conditions and apoptotic events: increased mRNA expression was detected for p53, 20S
proteasome alpha subunit, ABC1 transporter, p21(WAF1/CIP1), 14-3-3 sigma factor, MMP-9 and
MMP-14, and TIMP-1.
Based on the assumption that glaucoma patients may differ on the level of their expression
for these mRNAs, we expect that similar differences should exist at the protein level.
This study is, therefore, designed to characterize the proteome related to the proteins
involved in cell death related pathways.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A |